In a report released yesterday, from Berenberg Bank maintained a Buy rating on UCB SA, with a price target of €290.00. The company’s shares closed yesterday at €258.30.Elevate Your Investing Strategy:...
In a report released today, Charles Pitman CFA from Barclays reiterated a Buy rating on UCB SA, with a price target of €270.00. The company’s shares closed last Friday at €257.24.Elevate Your Investing...
TD Cowen analyst Stacy Ku maintained a Buy rating on UCB SA today and set a price target of €300.00. The company’s shares closed yesterday at €257.96.Elevate Your Investing Strategy: Take advantage...
Goldman Sachs analyst Rajan Sharma reiterated a Buy rating on UCB SA on September 29 and set a price target of €255.00. The company’s shares closed yesterday at €244.62.Elevate Your Investing Strategy:...
ATLANTA , Sept. 17, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced three- and four-year data from across the open-label extension (OLE) Phase 3 trials for BIMZELX...
ATLANTA , Sept. 17, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced three-year data from the BE HEARD trials for BIMZELX ® (bimekizumab-bkzx) in adults...
ATLANTA , Sept. 10, 2025 /PRNewswire/ --Â UCB, a global biopharmaceutical company, today shared results from the "Rheum for Improvement" survey that sought to further understand unmet...
BRUSSELS , Aug. 29, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced it will present 26 abstracts from its epilepsy portfolio at the International Epilepsy...
ATLANTA , Aug. 5, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, hosted its 2025 Hidradenitis Suppurativa (HS) Summit, which aimed to create a community forum for open discussion...